Patents by Inventor Guenther LAMETSCHWANDTNER

Guenther LAMETSCHWANDTNER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases
    Patent number: 10472341
    Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: November 12, 2019
    Assignees: APEIRON BIOLOGICS AG, EVOTEC SE
    Inventors: Monika Ermann, Guenther Lametschwandtner, Patricia Leonie Amouzegh, Russell Stuart Craft, Thomas Hanke, Timothy Robin James, Severine Danielle Jones, Hans Loibner, Pui Leng Loke, Ina Sternberger, Anton Stuetz, Roland Wehr, Mark Whittaker
  • BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES
    Publication number: 20180170888
    Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 21, 2018
    Inventors: Monika ERMANN, Guenther LAMETSCHWANDTNER, Patricia Leonie AMOUZEGH, Russell Stuart CRAFT, Thomas HANKE, Timothy Robin JAMES, Severine Danielle JONES, Hans LOIBNER, Pui Leng LOKE, Ina STERNBERGER, Anton STUETZ, Roland WEHR, Mark WHITTAKER
  • SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancer
    Patent number: 9186373
    Abstract: The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: November 17, 2015
    Assignee: Apeiron Biologics AG
    Inventors: Günther Lametschwandtner, Hans Loibner, Manfred Schuster, Isabella Haslinger, Sandra Seidl
  • SIRNA AGAINST CBL-B AND OPTIONALLY IL-2 AND IL-12 FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20140010781
    Abstract: The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.
    Type: Application
    Filed: December 27, 2011
    Publication date: January 9, 2014
    Applicant: APEIRON BIOLOGICS AG
    Inventors: Günther Lametschwandtner, Hans Loibner, Manfred Schuster, Isabella Haslinger, Sandra Seidl
  • Receptor In Dendritic Cells
    Publication number: 20090317827
    Abstract: The present invention provides the use of GPR91 as a target in dendritic cells.
    Type: Application
    Filed: May 2, 2006
    Publication date: December 24, 2009
    Applicant: NOVARTIS AG
    Inventors: José M. Carballido Herrera, Günther Lametschwandtner, Gudrun Werner, Antal Rot
  • GPR18 as a Biomaker for TH1 Mediated Immune Response
    Publication number: 20090208997
    Abstract: The present invention provides the use of GPR18 in diseases or disorders mediated by Th1 cell activation.
    Type: Application
    Filed: May 2, 2006
    Publication date: August 20, 2009
    Inventors: José M. Carballido Herrera, Claudia Guenther, Günther Lametschwandtner, Gudrun Werner